Method for quantifying expression of functionally active topoisomerase II in patients with leukaemia

A R Cattan, D Levett, E A Douglas, P G Middleton, P R A Taylor

Abstract

Aims—To produce a method to measure and quantify enzymatically active topoisomerase II in normal and neoplastic human cells.

Methods—A crude cell lysate from density separated mononuclear cells from either peripheral blood or bone marrow was prepared as a source of topoisomerases. Using the lysate, minicircles from the Crithidia kinetoplast DNA complex were decatenated before being separated by agarose gel electrophoresis and visualised using ethidium bromide/ultraviolet fluorescence.

Results—Cell number, sample volume and drug inhibition concentration required to produce reliable and reproducible assay conditions were established. Intra- and interassay standards were included which permitted the quantification of active topoisomerase II in matched peripheral blood, bone marrow, presentation, and relapse samples from patients with acute lymphoblastic leukaemia. Active topoisomerase II has been converted to a unit scale which has been used to compare topoisomerase II activities in cells from patients with normal blood and bone marrow samples.

Conclusions—There was no change in topoisomerase II activities between samples taken at presentation and those taken during a recurrence. However, topoisomerase II activity in leukaemic blast populations was increased compared with topoisomerase II activity in normal cells.


Keywords: drug resistance, topoisomerases, leukaemia.

At presentation, most acute leukaemias show some response to treatment; however, with time most adult patients succumb to their disease due to relapse. Following relapse, treatment protocols become less effective and drug concentrations are escalated with the addition of other chemotherapeutic agents. This phenomenon of failing response to therapy with increased tumour load is often referred to collectively as the development of drug resistance. There are many in vitro and in vivo models used to describe the development of drug resistance, including the multidrug resistance phenotype or MDR, drug detoxification, changes in both the level and structure of the drug target, and changes in DNA repair mechanisms. All of these mechanisms may work alone or in concert to produce the phenotype in vivo of the eventual failure of response to treatment seen in patients with leukaemia.

The topoisomerases are a ubiquitous family of enzymes seen in bacteria (DNA gyrases) and in eukaryote organisms where two major forms exist: topoisomerase I which catalyse single strand DNA breaks and ligations; and topoisomerase II which catalyse the cleavage and ligation of double strand DNA breaks. These enzymes are believed to play important roles in DNA replication, repair and in gene transcription (for review see ). In mammalian cells there are two forms (α and β) of topoisomerase II. Little is still known about their explicit roles although there are reported associations with the cell cycle and changes in expression of the two forms in cell lines under cytotoxic drug selection.

A variety of drugs used in the treatment of leukaemia, including the anthracyclines (daunorubicin, idarubicin), epipodophyllotoxins (VP-16) and anthraquinone (mitoxantrone), are known to target topoisomerase II, and may be partly responsible for the antineoplastic effects found. Attempts to measure activities of topoisomerase II and changes in their properties in mammalian cellular preparations have been largely restricted to cell lines. Topoisomerase II activities in clinical leukaemic samples have been reported using slot blots to detect specific mRNAs and by western blotting to detect protein and determine protein concentrations. As topoisomerase II expression has been shown to be decreased in cell lines exposed to cytotoxic agents, several groups have attempted to show a similar correlation in clinical specimens with the hope of relating this to clinical outcome. Although it has been reported that topoisomerase II expression changes during treatment, most investigations have been unable to correlate this expression with remission status. Ellis et al have described a filter based assay to quantify biologically active topoisomerase II in a cell line with the intention of using this method in an attempt to predict the development of drug resistance to the topoisomerases.

Quantification of topoisomerase II by either measurement of mRNA or specific protein and the use of this to correlate topoisomerase II activity with drug resistance phenotype does not take into account that the protein may be non-functional. It is known that phosphorylation status affects topoisomerase II function and that this may alter the antineoplastic effect of the drugs in question. In an attempt to address this problem, we have developed an assay to measure biologically active topoisomerase II in leukaemic samples. We report
the characterisation of this assay and the expression of functional topoisomerase II in leukemic blasts taken from patients with acute lymphoblastic leukaemia (ALL).

Methods

Patients

The diagnosis of leukaemia was made by a consultant haematologist using Romanovsky stained blood and marrow smears and was confirmed by appropriate cytochemical staining and immunophenotyping of the leukemic blasts. Details of the patients at presentation are shown in table 1. All cases were of de novo leukaemia except for patient ALL9 where the leukaemia was considered secondary to previous chemotherapy for Hodgkin’s disease. All patients received initial chemotherapy according to the NEALL III Protocol. Remission induction therapy was with vincristine, prednisolone, adriamycin, and cytosine. If complete remission (defined as <5% blasts in an adequately cellular marrow) was not achieved by seven weeks, then further intensive treatment with high dose cytosine and mitoxantrone was given. Four patients did not achieve complete remission. Two patients had recognised adverse factors (ALL6, Ph chromosome positive; ALL7, B-ALL) and a third (ALL8) evolved to acute myeloid leukaemia after five weeks on treatment. Consolidation treatment was with vincristine, steroids, cytosine, asparaginase, methotrexate, and 6-thioguanine. Patients for autograft and allograft were conditioned with high dose melphalan and total body irradiation.

Preparation of Cell Lysate

Mononuclear cells were separated from peripheral blood or bone marrow using Lymphoprep (Nycomed) and kept in the liquid nitrogen vapour phase. Pooled cells (5 × 10⁸) were washed once with phosphate buffered saline (PBS) containing 10 mM EDTA and the lysate prepared according to the method of Melendy and Ray. The harvested supernatant which formed the crude topoisomerase II lysate was used immediately and also stored diluted 1 in 1 with glycerol at −80°C.

Preparation of Crithidia DNA

Crithidia fasciculata (a gift of Dr I Hickson, Oxford) was grown in brain heart infusion medium (Difco) containing 10 μg/ml hemin, 100 μg/ml penicillin, 0.125 μg/ml streptomycin at 28°C to 1–5 × 10⁷/ml. DNA was prepared from the harvested protozoa (2 × 10⁸) using standard lysis and chloroform/alcohol extraction methods. The mixture of genomic and kinetoplast DNA was treated with RNase A (bovine pancreas; Sigma, Poole, Dorset, UK) for 60 minutes at 37°C (50 μg/ml final concentration) and then mixed with molecular weight marker (5:3 ratio Hind III digested bacteriophage λ markers; Integra Biosciences) to form the target DNA for the topoisomerase II assay.

Assay of Topoisomerase II Activity

The assay is an adaptation of the assay of Davies et al. Briefly, 5 μl reaction buffer (50 mM Tris (pH 7.9), 120 mM KCl, 10 mM MgCl₂, 0.5 mM EDTA, 30 μg/ml bovine serum albumin, 5 mM DTT, 5 mM ATP), 5 μl adriamycin (380 ng/ml in water), 24.5 μl water, 7.5 μl cell lysate, and 8 μl Crithidia/λ DNA phage were mixed in a microcentrifuge tube, incubated at 30°C for 30 minutes and the reaction stopped by the addition of 12.5 μl stop solution (5% w/v SDS, 30% glycerol, 2.5 μg bromophenol blue).

Protein Estimation

Protein content in lysates was measured according to the method of Bradford, adapted for use on a 96 well plate reader (Miltoniskan MCC 340).

Gel Electrophoresis and Densitometric Measurements

Assay samples were run for 16 hours in 0.8% (w/v) agarose standard DNA electrophoresis conditions and bands visualised with ethidium bromide. Following electrophoresis the resulting separations of DNA molecules were visualised by ultraviolet illumination of the DNA–ethidium complexes (302 nm transillumination) and the image stored electronically for further analysis (UVP 2000, Ultaviolet Products Ltd). The units of topoisomerase II were calculated by adjusting the ratio of the total area of topoisomerase II to λ marker bands to those produced by an aliquoted control lysate in that particular test and corrected to the relevant point on a standard curve (fig 1). This correction was made for each patient sample such that the units of topoisomerase II were calculated using the formula below:

\[ \text{Units/mI (topoisomerase II)} = \frac{\text{Lysate} \times \text{Correction Factor}}{\text{Control Lysate} \times \text{Correction Factor}} \]

These units were expressed as units/mg protein and as units/1 × 10⁷ cells.

Results

Titration of Control Lysate Concentration

After density separation, a topoisomerase II lysate was prepared from cells from a patient with chronic lymphocytic leukaemia (CLL) and aliquots were frozen at −80°C in 50% glycerol. These aliquots have been stable for 12 months without any appreciable loss of activity.

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis phenotype</th>
<th>Presenting WBC \times 10⁹/l</th>
<th>Remission status achieved</th>
<th>Anti-leukaemic chemotherapy given prior to sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control 73</td>
<td>M</td>
<td>B-ALL</td>
<td>Complete remission</td>
<td>Chlorambucil 832 mg, prednisolone 520 mg</td>
<td>Induction therapy + intensive therapy + consolidation + allograft</td>
<td></td>
</tr>
<tr>
<td>ALL1 23</td>
<td>F</td>
<td>ALL</td>
<td>Complete remission</td>
<td>Induction therapy + intensive therapy + consolidation + allograft</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL2 48</td>
<td>M</td>
<td>T-ALL</td>
<td>Complete remission</td>
<td>Induction therapy + intensive therapy + consolidation + allograft</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL3 39</td>
<td>M</td>
<td>preB-ALL 63.3</td>
<td>Complete remission</td>
<td>Induction therapy + intensive therapy + consolidation + allograft</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL4 16</td>
<td>M</td>
<td>ALL</td>
<td>Complete remission</td>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL5 62</td>
<td>F</td>
<td>ALL</td>
<td>Complete remission</td>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL6 16</td>
<td>M</td>
<td>ALL</td>
<td>Complete remission</td>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL7 21</td>
<td>M</td>
<td>ALL</td>
<td>Complete remission</td>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL8 47</td>
<td>F</td>
<td>ALL</td>
<td>Complete remission</td>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL9 * 42</td>
<td>F</td>
<td>preB-ALL 63.7</td>
<td>Complete remission</td>
<td>None</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Leukaemia secondary to treatment for Hodgkin’s disease; WBC = white blood cell.
decatenation/catenation reaction is dependent on the presence of ATP and Mg\(^{2+}\) ions and independent of the presence of *Crithidia* genomic DNA (fig 2). As similar results were found when purified kinetoplasts were used, all experiments reported were using the mixture of *Crithidia* genomic and kinetoplast DNA (table 2). When genomic DNA only was used, none of the characteristic forms of kinetoplast minicircles were found (results not shown).

<table>
<thead>
<tr>
<th>Drug</th>
<th>EC50 (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adriamycin</td>
<td>1.0</td>
</tr>
<tr>
<td>Elliptocine</td>
<td>12.5</td>
</tr>
<tr>
<td>Etoposide</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>N-ethylmaleimide</td>
<td>&gt;500</td>
</tr>
<tr>
<td>Novobiocin</td>
<td>&gt;500</td>
</tr>
</tbody>
</table>

**Figure 1** (A) Titration of cell lysate volume for the internal control and standard topoisomerase II assay. The x-axis shows the ratio of all topoisomerase II bands to Hind III digests of \(\lambda\) phage densometric areas and the x-axis cell lysate volumes. Points expressed are means for five separate experiments with bars showing standard deviation. (B) The x-axis shows an Adriamycin inhibition curve of decatenation/catenation of kinetoplast DNA using the CLL standard cell lysate. Points expressed are means for 10 separate experiments with bars showing standard deviation.

**Drug inhibition phenotype in the topoisomerase II assay**
To determine the sensitivity of the assay to various chemotherapeutic drugs, assays were done with various concentrations of drugs known to inhibit topoisomerase II (adriamycin, elliptocine, etoposide, N-ethylmaleimide, novobiocin). Table 2 shows the concentrations of various drugs required to inhibit by 50% the decatenation and catenation of kinetoplast DNA using the internal standard (CLL). This

**Titration of Adriamycin Concentration**
Using adriamycin, one of the drugs reported to inhibit topoisomerase II, we constructed an inhibition curve for the decatenation/catenation of kinetoplast DNA (fig 1B). The 50% inhibition of release of kinetoplast minicircles occurred at 38 ng/ml (72 nM) in our assay system. Adriamycin was subsequently added to each topoisomerase II assay at a final concentration of 38 ng/ml. This amount was found empirically to give a smaller standard deviation in the decatenation/catenation ability of the internal control and test sample triplicates (data not shown). At this concentration, small changes in topoisomerase II activities result in large changes in optical density and as a consequence in topoisomerase II expressed as our defined units. With each experiment, an aliquot of the CLL control topoisomerase II lysate was included with this fixed concentration of adriamycin. We adjusted the value found with the internal control to that expected from the standard curve, to control for interassay variability and to provide the correction factor in order to compare different patient samples.

**Topoisomerase II activities in acute lymphoblastic leukaemia cells**
Cells were isolated using differential density centrifugation from peripheral blood or bone marrow of patients with ALL. In 4 cases matched pairs of peripheral blood and bone marrow or in a further four cases presentation and relapse samples were available for comparison of their topoisomerase II activities (fig 2). The cell source, the percentage of leukaemic blasts in the sample, the presentation/ remission status of the patient at the time of sampling and the number of topoisomerase II units both as per mg of cellular protein and per 1 \(\times\) 10\(^7\) cells are shown in table 3; fig 3. The mean and standard deviation for topoisomerase II units for 10 peripheral blood mononuclear cell samples and for eight bone marrow mononuclear cell samples from normal subjects are also shown. There was no consistent pattern of change between presentation and relapse samples. The protein concentrations vary with both increases (ALL3) and decreases

**Table 2** Concentrations of drugs required to inhibit decatenation/catenation of kinetoplast DNA by 50%
Table 3 Topoisomerase II and protein concentrations in patient and normal tissue samples. Results expressed as mean (SD)

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Stage</th>
<th>Source</th>
<th>Leukaemic blast (%)</th>
<th>Protein (mg/ml)</th>
<th>Specific activity (U/ml)</th>
<th>Units/cell \times 10^7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard</td>
<td>Peripheral</td>
<td>NA</td>
<td>0.2</td>
<td>0.58</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Normal (n = 10)</td>
<td>Peripheral</td>
<td>NA</td>
<td>0.81 (0.28)</td>
<td>0.69 (0.45)</td>
<td>0.13 (0.09)</td>
<td></td>
</tr>
<tr>
<td>Normal (n = 8)</td>
<td>Bone marrow</td>
<td>NA</td>
<td>1.19 (0.76)</td>
<td>0.7 (0.59)</td>
<td>0.13 (0.1)</td>
<td></td>
</tr>
<tr>
<td>ALL1</td>
<td>Presentation</td>
<td>Peripheral blood</td>
<td>1.24</td>
<td>0.93</td>
<td>0.24</td>
<td></td>
</tr>
<tr>
<td>ALL2</td>
<td>Relapse</td>
<td>Peripheral blood</td>
<td>1.2</td>
<td>1.08</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>ALL3</td>
<td>Presentation</td>
<td>Peripheral blood</td>
<td>1.13</td>
<td>0.9</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>ALL4</td>
<td>Relapse</td>
<td>Peripheral blood</td>
<td>1.13</td>
<td>1.26</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>ALL5</td>
<td>Presentation</td>
<td>Peripheral blood</td>
<td>1.44</td>
<td>0.78</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>ALL6</td>
<td>RELAPSE</td>
<td>Peripheral blood</td>
<td>1.18</td>
<td>1.05</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>ALL7</td>
<td>Presentation</td>
<td>Bone marrow</td>
<td>1.05</td>
<td>1.1</td>
<td>0.23</td>
<td></td>
</tr>
<tr>
<td>ALL8</td>
<td>Presentation</td>
<td>Peripheral blood</td>
<td>1.18</td>
<td>1.23</td>
<td>0.21</td>
<td></td>
</tr>
<tr>
<td>ALL9</td>
<td>Presentation</td>
<td>Bone marrow</td>
<td>0.55</td>
<td>1.97</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>ALL10</td>
<td>Presentation</td>
<td>Bone marrow</td>
<td>0.87</td>
<td>1.23</td>
<td>0.21</td>
<td></td>
</tr>
<tr>
<td>ALL11</td>
<td>Presentation</td>
<td>Bone marrow</td>
<td>0.52</td>
<td>2.45</td>
<td>0.26</td>
<td></td>
</tr>
<tr>
<td>ALL12</td>
<td>Presentation</td>
<td>Bone marrow</td>
<td>0.68</td>
<td>1.75</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>ALL13</td>
<td>Presentation</td>
<td>Bone marrow</td>
<td>0.69</td>
<td>1.55</td>
<td>0.21</td>
<td></td>
</tr>
<tr>
<td>ALL14</td>
<td>Presentation</td>
<td>Bone marrow</td>
<td>0.82</td>
<td>1.18</td>
<td>0.19</td>
<td></td>
</tr>
</tbody>
</table>

NA = not applicable.

(ALL1) between presentation and relapse when most of the protein measured can be accounted for by the leukaemic blast population. In one patient (ALL1) there is a noticeable increase in the specific activity (U/mg) of topoisomerase II measured between presentation and relapse whereas in a further two there is no significant change between presentation and relapse samples (ALL2 and 4). Only one patient (ALL3) shows a decrease in topoisomerase II specific activity. Differences in matched pairs of peripheral blood mononuclear cell and bone marrow mononuclear cell protein concentrations mirror changes in the percentage of leukaemic blasts in the sample. The specific activity for these matched pairs shows lower levels of topoisomerase II activity found with increasing leukaemic blast percentages in the samples.

**Discussion**

The protozoan, *Crithidia fasiculata*, contains a mitochondrial genome of unusual structure. Most of the genetic information is contained on circular DNA molecules, maxicircles, which are linked together with a larger number of smaller minicircle DNA molecules, collectively known as the kinetoplast. Only topoisomerase II can successfully release (decatenate) and rejoin (catenate) minicircles from the kinetoplast.

Cells from a patient with CLL were chosen as the standard control as there was a reasonable quantity of topoisomerase II activity in the peripheral CLL cells and because of the nature of this disease, it was possible to obtain a single large donation of peripheral CLL cells to act as an internal standard. Aliquots of this internal standard lysate have been found to be stable for up to 12 months if stored in glycerol at −80°C. Other workers have reported that the activities of topoisomerase II are low in CLL\(^6\) and that this may be a reason...
why these patients become refractory to topo-

isomerase II inhibitory drugs. The CLL cells used as control in these experiments have higher topoisomerase II activities than a variety of haemopoietic cell lines (unpublished results) but similar to other samples from patients with CLL in our hands. These differences can be explained if there is translational control such that large amounts of active topoisomerase II are produced as has been reported for other proteins. Given the vast numbers of circulating cells in CLL, there would be a large reservoir of the topoisomerase II target for the cytotoxic drugs. It is interesting to note that the specific activity and activity per cell for the CLL control gave values approximating those seen in normal cells (table 3; fig 3).

The amount of enzymatically active topo-
isomerase II found in samples from patients with ALL is generally twice the level found in normal peripheral blood mononuclear cells or in bone marrow (mean (SD) 1.36 (0.11) and 0.69 (0.12), respectively). Normal peripheral blood mononuclear cells and bone marrow mononuclear cells give very similar activities of functional topoisomerase II and although there are different protein concentrations in the two cell populations, both peripheral blood mono-
nuclear cells and bone marrow have similar specific activities and activities per cell (table 3; fig 3). Patient samples taken from bone marrow or blood gave comparable concentra-
tions of active enzyme as long as the percentage blasts present were similar. Patient ALL5 had a lower number of leukaemic blasts in the presentation sample. The level of topoisomerase II activity in patient ALL5 is, therefore, an expression of the amount of topoisomerase II in the peripheral blood mononuclear cells in this sample and lies within the standard devia-
tion seen in these cells in normal samples (table 3; fig 3).

Ellis et al26 have reported a filter binding assay to measure topoisomerase II–DNA com-
plexes in the presence of crosslinking drugs and hope to use this as a means of measuring drug sensitivity in freshly isolated leukaemic blast populations. McKenna et al27 have reported that there is no correlation between clinical outcome and topoisomerase II mRNA levels in acute myeloid leukaemia, although they state that as their sample size is small a multicentre study might be warranted. We have been unable to find particularly low concentra-
tions of active topoisomerase II in CLL either at presentation or in longitudinal samples showing signs of clinical resistance to treat-
ment (data not shown). Taking these com-
ments and our findings into consideration, we believe that measurements of enzymatically active topoisomerase II may correlate better with clinical outcome in those diseases show-
ing clinical resistance to topoisomerase II inhibitors. We are currently investigating active topoisomerase II concentrations in a panel of

haemopoietic tumours to see whether these concentrations correlate with clinical progres-
sion.

The financial support of the Tynneside Leukaemia Research Fund is gratefully acknowledged.

4. Nitis JL, Liu YX, Hsiung Y. A temperature sensitive topo-
5. Erickson LR. The role of O-6-methylguanine DNA methyl-
6. Hall AG, Cattn AR. Drug resistant mechanisms in leuke-


191-218.
ution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant II-60 human leukemia cell line. Cancer Res 1993;53:1517-6.
14. Burden DA, Sullivan DM. Phosphorylation of the α- and β-isomers of DNA topoisomerase II is qualitatively differ-
15. McKenna SL, West RB, Whitaker JA, Padua RA, Holmes JA. Topoisomerase II α expression in acute myeloid leuke-
17. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, et al. Topoisomerase II levels and drug sensi-
tivity in adult acute myelogenous leukaemia. Blood 1994;83:

517-30.
21. Melendy T, Ray DS. Novobiocin affinity purification of a mitochondrial type II topoisomerase from the trypano-

22. Davies SM, Ro bson CN, Davies SL, Hickson ID. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyl-

23. Bradford MM. A rapid and sensitive method for the quanti-
atation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:

248-54.
24. McKenna SL, Whitaker JA, Padua RA, Holmes JA. Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia. Drug sensitivity or resis-
tance. Leukemia 1993;7:1199-203.
Method for quantifying expression of functionally active topoisomerase II in patients with leukaemia.

A R Cattan, D Levett, E A Douglas, P G Middleton and P R Taylor

doi: 10.1136/jcp.49.10.848

Updated information and services can be found at:
http://jcp.bmj.com/content/49/10/848

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/